LACTOFERIN IN THE PROBLEM OF ANTI-INFECTIOUS PROTECTION OF BABIES IN THEIR FIRST YEAR OF LIVING

The author  summarizes  the  results  of research  of the  antibacterial,  antiviral  and  antifungal  properties  of multifunctional  human protein  — lactoferrin,  in order  to determine  the prospects  for its use in the prevention  and  treatment  of infectious  diseases  of children in their first year of life. The mechanisms of anti-infectious effect of this protein with breastfed children have been described. Basic differences between human lactoferrin and cattle lactoferrin have been shown. Biotechnology of obtaining recombinant human lactoferrin from the milk of genetically engineered dairy animals (goat-producers) has been described. According to the studies, both by physical and chemical parameters and biological activity, human lactoferrin, obtained from milk-producing  goats, corresponds to its natural counterpart

БИФИДОГЕННЫЕ СВОЙСТВА БИОТЕХНОЛОГИЧЕСКОГО АНАЛОГА ЛАКТОФЕРРИНА ЧЕЛОВЕКА

Background:  Recent research shows that the growth and development of the gastrointestinal  tract of children fed by breast milk is more intense than that of the formula fed, since the human lactoferrin contained in the breast milk is a factor that stimulates cell growth. Therefore, the possibility of using exogenous lactoferrin will be of great importance in the nutrition of infants.Objektive: To study the bifidogenic properties of the biotechnological analogue of human lactoferrin. Methods: Kinetics of growth and CFU titer of bifidobacterial culture in the presence of a biotechnological analogue of human lactoferrin (0,05–5 mg /ml) was determined.Results: It has been shown that different concentrations of the protein can have both a stimulating (for B. bifidum and B. infantis) and inhibitory (for B. longum) effect on the growth of bifidobacteria, which is due to the affinity of lactoferrin binding to them. It seems important to further study the stimulating effect of this protein on the growth of lactobacilli in the intestine of the child.Conclusion:  Due to bifidogenic and high bactericidal action, lactoferrin can be effective in feeding newborns.Обоснование.   Новейшие исследования  показывают,  что  рост  и развитие  желудочно-кишечного  тракта  детей, вскармливаемых  материнским молоком,  происходит  интенсивнее,  чем у вскармливаемых  молочными смесями, поскольку содержащийся в нем лактоферрин человека является фактором, стимулирующим клеточный рост. Именно поэтому возможность  использования экзогенного лактоферрина  будет иметь большую значимость в питании грудных детей.Цель  исследования — изучить бифидогенные  свойства биотехнологического аналога  лактоферрина человека.Методы. Определялась кинетика роста и КОЕ-титр культивирования бифидобактерий в присутствии биотехнологического  аналога лактоферрина человека.Результаты. Показано, что различные концентрации данного белка (0,05–5 мг/мл) могут оказывать как стимулирующее (для Bifidobacterium bifidum и Bifidobacterium infantis), так и ингибирующее (для Bifidobacterium longum) действие в отношении роста бифидобактерий,  что обусловлено аффинностью  связывания с ними лактоферрина. Представляется  важным дальнейшее изучение стимулирующего эффекта  этого белка на рост лактобацилл в кишечнике ребенка.Заключение. Благодаря  бифидогенному и выраженному бактерицидному действию лактоферрин может быть использован в лечебном питании новорожденных

ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ЛАКТОФЕРРИНА У ДЕТЕЙ ПЕРВОГО ГОДА ЖИЗНИ

The author  summarizes  the  results  of research  of the  antibacterial,  antiviral  and  antifungal  properties  of multifunctional  human protein  — lactoferrin,  in order  to determine  the prospects  for its use in the prevention  and  treatment  of infectious  diseases  of children in their first year of life. The mechanisms of anti-infectious effect of this protein with breastfed children have been described. Basic differences between human lactoferrin and cattle lactoferrin have been shown. Biotechnology of obtaining recombinant human lactoferrin from the milk of genetically engineered dairy animals (goat-producers) has been described. According to the studies, both by physical and chemical parameters and biological activity, human lactoferrin, obtained from milk-producing  goats, corresponds to its natural counterpart.В статье обобщены результаты исследований, посвященных изучению антибактериальных, противовирусных и противогрибковых свойств многофункционального белка человека — лактоферрина, для определения перспектив его применения с целью профилактики и лечения инфекционной патологии у детей первого года жизни. Описаны механизмы противоинфекционного действия этого белка у детей, находящихся на грудном вскармливании. Показаны основные различия между лактоферрином человека и лактоферрином крупного рогатого скота. Описана биотехнология получения рекомбинантного лактоферрина человека из молока генно-инженерных молочных животных (коз-продуцентов). Согласно проведенным исследованиям, как по физико-химическим параметрам, так и по биологической активности лактоферрин  человека, выделенный из молока коз-продуцентов, соответствует его природному аналогу

THE MOLECULAR MECHANISM OF LACTOFERRIN INFLUENCE ON BONE FORMATION

In present critical review of systematized materials on the breakthrough achievements of the last decade - the discovery of the effect of protein lactoferrin (LF) on bone formation. It is shownthat LF increases the number of osteoblasts, stimulate their proliferation and differentiation, and prevents their destruction. Action of LF exceeds that of many other previously established bone-forming factors. LF increases the ability of osteoblasts to synthesize and mineralize bone matrix. Apparently, the effect of LF on bone anabolism ensured by the presence of specific receptors on osteoblasts. It was found that LF also inhibits the formation of osteoclasts. Experimental studies have demonstrated that LF prevents the destruction of bone tissue in ovariectomizedanimals and, thus, developing the type of postmenstrual osteoporosis in women. We get the first clinical studies demonstrating an increase in the period of healing of bone injuries while reducing the level of endogenous LF. Since molecular research establishes that the expression of the LF gene is regulated by estrogen, which reduces the development of postmenopausal osteoporosis (PMO) in women, there is a need to further investigate the relationship of these processes, which will help to create a basis for the management of bone formation

BIFIDOGENIC PROPERTIES OF A BIOTECHNOLOGICAL ANALOGUE OF HUMAN LACTOFERRIN

Background:  Recent research shows that the growth and development of the gastrointestinal  tract of children fed by breast milk is more intense than that of the formula fed, since the human lactoferrin contained in the breast milk is a factor that stimulates cell growth. Therefore, the possibility of using exogenous lactoferrin will be of great importance in the nutrition of infants.Objektive: To study the bifidogenic properties of the biotechnological analogue of human lactoferrin. Methods: Kinetics of growth and CFU titer of bifidobacterial culture in the presence of a biotechnological analogue of human lactoferrin (0,05–5 mg /ml) was determined.Results: It has been shown that different concentrations of the protein can have both a stimulating (for B. bifidum and B. infantis) and inhibitory (for B. longum) effect on the growth of bifidobacteria, which is due to the affinity of lactoferrin binding to them. It seems important to further study the stimulating effect of this protein on the growth of lactobacilli in the intestine of the child.Conclusion:  Due to bifidogenic and high bactericidal action, lactoferrin can be effective in feeding newborns

A mice model of amyotrophic lateral sclerosis expressing mutant human FUS protein

BACKGROUND AND ОBJECTIVE: Loss of conformation and function of sufficient number of proteins with high aggregation capacity plays an important role in the pathogenesis of many neurodegenerative disorders (NDD). Due to a recent discovery of new array of proteins with the capacity to form aggregates of nonamyloid type, new NDD models as well as a new level of understanding in vivo models which are already exist is needed. DNA/RN A binding proteins - FUS and TDP-43 play a crucial role in the pathogenesis of some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The objective of the study was to develop a new ALS transgenic model. MATERIAL AND METHODS: In cell culture experiments, we studied mutant FUS proteins capable to form intracellular deposits morphologically similar to those observed in the autopsy material of ALS patients. RESULTS AND CONCLUSION: We created a transgenic mice line, in which a pathogenic form of human FUS protein was expressed in the nervous system. That led to the aggregation of FUS protein in spinal cord and motor neurons with the following degeneration and development of a phenotype, similar to the human ALS disease phenotype, in young grown-up animals. This neurodegenerative phenotype corresponds to a great number of clinical manifestations of human ALS and is an adequate transgenic model of the disease

A mice model of amyotrophic lateral sclerosis expressing mutant human FUS protein

BACKGROUND AND ОBJECTIVE: Loss of conformation and function of sufficient number of proteins with high aggregation capacity plays an important role in the pathogenesis of many neurodegenerative disorders (NDD). Due to a recent discovery of new array of proteins with the capacity to form aggregates of nonamyloid type, new NDD models as well as a new level of understanding in vivo models which are already exist is needed. DNA/RN A binding proteins - FUS and TDP-43 play a crucial role in the pathogenesis of some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The objective of the study was to develop a new ALS transgenic model. MATERIAL AND METHODS: In cell culture experiments, we studied mutant FUS proteins capable to form intracellular deposits morphologically similar to those observed in the autopsy material of ALS patients. RESULTS AND CONCLUSION: We created a transgenic mice line, in which a pathogenic form of human FUS protein was expressed in the nervous system. That led to the aggregation of FUS protein in spinal cord and motor neurons with the following degeneration and development of a phenotype, similar to the human ALS disease phenotype, in young grown-up animals. This neurodegenerative phenotype corresponds to a great number of clinical manifestations of human ALS and is an adequate transgenic model of the disease